



PRESS RELEASE

Change in number of shares and votes in Moberg Pharma

STOCKHOLM, December 30th, 2016. The number of shares and votes in Moberg Pharma AB (publ) ("Moberg Pharma") has increased by 3,122,654 in December 2016. Therefore, there are in total 17,411,842 shares and votes in the company as of 30 December 2016.

The total number of shares and votes has increased as a result of the directed share issue of in total 2,843,504 shares that Moberg Pharma announced on 7 December 2016 and as a result of 279,150 shares issued after exercise of warrants under Moberg Pharma's share-based incentive program. As a result of the new issue of shares and the exercise of the warrants, the total number of shares and votes has increased by 3,122,654 from 12,289,188 to 17,411,842 and the share capital has increased by SEK 312,265.40 from SEK 1,428,918.80 to SEK 1,741,184.20.

For additional information, please contact:

Peter Wolpert, CEO, Phone: +46 707 35 71 35, E-mail: peter.wolpert@mobergpharma.se

Anna Ljung, CFO, Phone: +46 707 66 60 30, E-mail: anna.ljung@mobergpharma.se

About this information

This information is such that Moberg Pharma AB (publ) is obliged to disclose pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 a.m. (CET) on December 30th, 2016.

About Moberg Pharma, www.mobergpharma.com

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company's portfolio includes the OTC brands Kerasal[®], Kerasal Nail[®], Balmex[®], NewSkin[®], Domeboro[®] and Fiber Choice[®]. Kerasal Nail[®] (Emtrix[®] or Nalox[™] in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focuses on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company's shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).